July 2020 Clinical Watch Newsletter

August 4, 2020

Share this Flipbook
Facebook
Twitter
Email
LinkedIn

In this issue of Clinical Watch, we discuss new antipsychotic medication formulations to tailor the management of schizophrenia and suggest prior authorization criteria for a new treatment for Cushing’s disease. Lastly, we review claims data to identify the trends for use of Dupixent®.
For more information about a topic, please contact Janelle Sheen, Karen Powell or Mary-Beth Plum. Be sure to watch for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.

Five Strategies to Bring Your Community Health Needs Assessment to Life

Conduent’s New Rank on the Everest Group PEAK Matrix Signals More Value for Our Clients

Other content in this Stream

September 2020 Clinical Watch Newsletter

July 2020 Clinical Watch Newsletter

Previous Article

Next Article

Other content in this Stream

Advanced digital capabilities take the stress out of the busiest time of the year

In this issue of Clinical Watch, we discuss nitrosamine impurities found in widely used medications and suggest prior authorization criteria for a new treatment for heavy menstrual bleeding

In this issue of Clinical Watch, we highlight the use of diabetes drugs in the treatment of heart failure and suggest prior authorization criteria for the first approved treatment of plexiform neurofi

Public health professionals have been sounding the alarm for years, but the COVID-19 pandemic and the sweeping protests following the death of George Floyd have brought the message front and center

In this issue of Clinical Watch, we highlight the NIH Panel recommendations regarding medications associated with COVID-19 treatment and suggest prior authorization criteria for the first approved tre

In this issue of Clinical Watch, we highlight aspects of Medicaid programs that are affected COVID-19 and suggest prior authorization criteria for a new lipid-lowering drug.

Pharmaceutical manufacturers and payers are often at odds over pricing and barriers to new medication access. Payers will typically initiate a variety of cost containment initiatives,

In this issue of Clinical Watch, we discuss COVID-19 and suggest prior authorization criteria for immunotherapy to reduce the severity of allergic reactions to peanuts.

Augmented Reality enables the physical environment or object to become a digital portal to relevant, personalized information that can be tailored to inform users...

In this issue of Clinical Watch, we discuss the expanded indication for drugs to treat relapsing forms of multiple sclerosis.